These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 17071064)

  • 21. Dyslipidaemia in diabetic patients: time for a rethink.
    Shepherd J
    Diabetes Obes Metab; 2007 Sep; 9(5):609-16. PubMed ID: 17697054
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [PPAR agonists do not come up to expectations. Hope about the preventive effect in type 2 diabetes has come to nought].
    Olsson AG
    Lakartidningen; 2006 Aug 30-Sep 5; 103(35):2454-5. PubMed ID: 17002160
    [No Abstract]   [Full Text] [Related]  

  • 23. Solvay addresses unmet needs in the management of hypertensive patients with cardiometabolic and lipid disorders.
    Cardiovasc J Afr; 2009; 20(1):73-4. PubMed ID: 19287821
    [No Abstract]   [Full Text] [Related]  

  • 24. Effectiveness of a fenofibrate 145-mg nanoparticle tablet formulation compared with the standard 160-mg tablet in patients with coronary heart disease and dyslipidemia.
    Maciejewski S; Hilleman D
    Pharmacotherapy; 2008 May; 28(5):570-5. PubMed ID: 18447655
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen study).
    May HT; Anderson JL; Pearson RR; Jensen JR; Horne BD; Lavasani F; Yannicelli HD; Muhlestein JB
    Am J Cardiol; 2008 Feb; 101(4):486-9. PubMed ID: 18312763
    [TBL] [Abstract][Full Text] [Related]  

  • 26. What to make of ACCORD. Surprising new results from the landmark diabetes study.
    Johns Hopkins Med Lett Health After 50; 2010 Sep; 22(7):1-2, 7. PubMed ID: 20848750
    [No Abstract]   [Full Text] [Related]  

  • 27. Metabolic syndrome, diabetes and coronary heart disease.
    Haffner SM
    Int J Clin Pract Suppl; 2002 Oct; (132):31-7. PubMed ID: 12425361
    [No Abstract]   [Full Text] [Related]  

  • 28. Statins and fibrates in the management of diabetic dyslipidemia.
    Durrington P
    Diabet Med; 1997 Jul; 14(7):513-6. PubMed ID: 9223386
    [No Abstract]   [Full Text] [Related]  

  • 29. Dramatic resolution of massive retinal hard exudates after correction of extreme dyslipidaemia.
    Waller S; Thyagarajan S; Kaplan F; Viljoen A
    Eye (Lond); 2009 Mar; 23(3):738. PubMed ID: 18437181
    [No Abstract]   [Full Text] [Related]  

  • 30. Low HDL-cholesterol is common in European Type 2 diabetic patients receiving treatment for dyslipidaemia: data from a pan-European survey.
    Bruckert E; Baccara-Dinet M; Eschwege E
    Diabet Med; 2007 Apr; 24(4):388-91. PubMed ID: 17335463
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lipid-lowering therapy in patients with type 2 diabetes: the case for early intervention.
    Steinmetz A
    Diabetes Metab Res Rev; 2008; 24(4):286-93. PubMed ID: 18273835
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treating dyslipidaemia in the setting of diabetes mellitus and cardiovascular disease: another focus.
    Tahrani AA
    Int J Clin Pract; 2006 Nov; 60(11):1515; author reply 1515-6. PubMed ID: 17073848
    [No Abstract]   [Full Text] [Related]  

  • 33. Fenofibrate therapy and cardiovascular protection in diabetes: recommendations after FIELD.
    Vergès B
    Curr Opin Lipidol; 2006 Dec; 17(6):653-8. PubMed ID: 17095910
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study.
    Van Ganse E; Laforest L; Burke T; Phatak H; Souchet T
    Clin Ther; 2007 Aug; 29(8):1671-81. PubMed ID: 17919548
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in patients with diabetes mellitus and mixed dyslipidemia.
    Athyros VG; Kakafika AI; Karagiannis A; Mikhailidis DP
    Am J Cardiol; 2008 Jun; 101(11):1679-80. PubMed ID: 18489951
    [No Abstract]   [Full Text] [Related]  

  • 36. Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.
    Goff DC; Gerstein HC; Ginsberg HN; Cushman WC; Margolis KL; Byington RP; Buse JB; Genuth S; Probstfield JL; Simons-Morton DG;
    Am J Cardiol; 2007 Jun; 99(12A):4i-20i. PubMed ID: 17599424
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fenofibric Acid (trilipix).
    Med Lett Drugs Ther; 2009 May; 51(1311):33-4. PubMed ID: 19417718
    [No Abstract]   [Full Text] [Related]  

  • 38. [Treatment of dyslipidemias and its benefits].
    Taskinen MR
    Duodecim; 1999; 115(10):1138-44. PubMed ID: 11877853
    [No Abstract]   [Full Text] [Related]  

  • 39. Therapy and clinical trials.
    Usman M; Peter R
    Curr Opin Lipidol; 2006 Oct; 17(5):612-4. PubMed ID: 16960511
    [No Abstract]   [Full Text] [Related]  

  • 40. Fenofibrate: treatment of hyperlipidemia and beyond.
    Rosenson RS
    Expert Rev Cardiovasc Ther; 2008 Nov; 6(10):1319-30. PubMed ID: 19018684
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.